共 37 条
- [31] Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (Recurindex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 761 - 773
- [33] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
- [34] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE VALUE IN HEALTH, 2017, 20 (09) : A422 - A423
- [35] Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
- [36] COST EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
- [37] Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)